JSJames Stimson

James Stimson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James Stimson has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Factors driving increases in Clostridioides difficile infection rates in England: a national case−control study, 2019 to 2024

    by Tim Whiteley, Andre Charlett, Dimple Chudasama, Zahin Amin-Chowdhury, Russell Hope, Laura Fellowes, Dakshika Jeyaratnam, Rebecca Oettle, Julie V Robotham, Charlotte Stevens, et al.

    BACKGROUND: Numbers of Clostridioides difficile infections (CDI) in England have risen since 2021, but for unclear reasons. AIM: This study’s objective was to understand factors driving CDI increases, and their relative impact. METHODS: We conducted a case–control study in England from 2019/20 to 2023/24, with CDI case data linked to hospitalisation episodes. Controls were non-CDI related hospitalisation episodes. A logistic regression model estimated odds ratios (ORs) for primary care prescribing, comorbidities, demographic factors, region and testing rates. To assess temporal changes, the model was fitted to 2019/20 data to predict, from 2020/21 onwards, case numbers, which were compared to observations. The relative contribution of factors to the model performance was evaluated by their stepwise inclusion into it, starting from a baseline considering hospitalisation numbers. Prediction improvements were assessed after each incorporation. RESULTS: The strongest CDI risk factors were prescriptions (e.g. OR for clindamycin: 5.22; p < 0.001), comorbidities (OR: 1.17; p < 0.001), and age (OR: 1.03; p < 0.001). All ethnicities except White negatively associated with CDIs. Among regions, the North West and Yorkshire and Humber had the highest ORs (1.17 and 1.15 respectively; p < 0.001). Demographic changes and antibiotic use explained 12.6% of the difference between observed cases in 2023/24 and our baseline model whereas including comorbidities and testing rates explained 65.3%. CONCLUSION: Increases in overall hospital admissions, comorbidities and testing largely explained rising case numbers, which also stemmed from an ageing population, demographic changes and more primary care antibiotic prescribing . Nevertheless, these factors did not fully account for observed increases, so further determinants should be sought.

  • Open Access

    Factors driving increases in Clostridioides difficile infection rates in England: A national case-control study, 2019 to 2024

    by Timothy Whiteley, Andre Charlett, Dimple Chudasama, Zahin Amin-Chowdhury, Russell Hope, Laura Fellowes, Dakshika Jeyaratnam, Rebecca Oettle, Julie Robotham, Charlotte Stevens, et al.

    Background: Numbers of Clostridioides difficile infections (CDI) in England have increased since 2021. The factors driving the increase are unknown. We aimed to understand the factors associated with CDI and what proportion of this recent increase could be explained by changes to these risk factors. Methods: Case-control study, with CDI case data linked to hospitalisation episodes. Control cases were non-CDI related hospitalisation episodes. A logistic regression model estimated odds ratios (ORs) for individual and regional demographic factors, comorbidities, testing rates and primary care antibiotic consumption. To assess temporal changes, the model was fitted to data from financial year 2019/20 and used to predict cases in 2020/21 onwards, compared to observed data. Results: Factors associated with testing positive for CDI were age, white ethnicity, comorbidities and primary care prescribing. The regions with the highest ORs were the North West and Yorkshire and Humber. Predicting cases using 2019/20 coefficients showed that demographic changes and antibiotic use explained 12.5% of the difference between observed cases and our baseline model in 2023/24. Including comorbidities and testing rates explained 63% of this increase. Conclusion: The strongest risk factors for CDI were age and antibiotic consumption. Increased hospitalisations, comorbidities and testing explained a large proportion of the rise in CDI cases whereas an ageing population, increases in antibiotic prescribing and demographic changes predicted smaller increases in CDI cases. However, the factors considered were not enough to fully explain the rise in cases and further investigation is needed into other factors that may be contributing.


  • Open Access

    Modeling the impact of health care worker masking to reduce nosocomial SARS-CoV-2 transmission under varying adherence, prevalence, and transmission settings.

    by Timothy D Whiteley, James Stimson, Colin S Brown, Julie V Robotham, Stephanie Evans

    Objectives: To understand the scenarios where health care worker (HCW) masking is most impactful for preventing nosocomial transmission. Methods: A mathematical agent-based model of nosocomial spread with masking interventions. Masking adherence, community prevalence, disease transmissibility, masking effectiveness, and proportion of breakroom (unmasked) interactions were varied. The main outcome measure is the total number of nosocomial infections in patients and HCW populations over a simulated three-month period. Results: HCW masking around patients and universal HCW masking reduces median patient nosocomial infections by 15% and 18%, respectively. HCW-HCW interactions are the dominant source of HCW infections and universal HCW masking reduces HCW nosocomial infections by 55%. Increasing adherence shows a roughly linear reduction in infections. Even in scenarios where a high proportion of interactions are unmasked “breakroom” interactions, masking is still an effective tool assuming adherence is high outside of these areas. The optimal scenarios where masking is most impactful are those where community prevalence is at a medium level (around 2%) and transmissibility is high. Conclusions: Masking by HCWs is an effective way to reduce nosocomial transmission at all levels of mask effectiveness and adherence. Increases in adherence to a masking policy can provide a small but important impact. Universal HCW masking policies are most impactful should policymakers wish to target HCW infections. The more transmissible a variant in circulation is, the more impactful HCW masking is for reducing infections. Policymakers should consider implementing masking at the point when community prevalence is optimum for maximum impact.


  • Open Access

    Modelling the impact of healthcare worker masking to reduce nosocomial SARS-CoV-2 transmission under varying adherence, prevalence, and transmission settings.

    by Timothy Whiteley, James Stimson, Colin Brown, Julie Robotham, Stephanie Evans

    Objectives To understand the scenarios where health care worker (HCW) masking is most impactful for preventing nosocomial transmission. Methods A mathematical agent-based model of nosocomial spread with masking interventions was used. Masking adherence, community prevalence, disease transmissibility and proportion of breakroom (unmasked) interactions were varied. The effectiveness of masks for reducing transmission to and from the wearer was also varied. The main outcome measure is the total number of nosocomial infections in patients and health care worker populations over a simulated three-month period. Results HCW masking around patients and universal HCW masking reduces median patient nosocomial infections by 15% and 18% respectively. HCW-HCW interactions are the dominant source of HCW infections and universal HCW masking reduces HCW nosocomial infections by 55%. Increasing adherence shows a roughly linear reduction in infections. Even in scenarios where a high proportion of interactions are unmasked ‘breakroom’ interactions, masking is still an effective tool assuming adherence is high outside of these areas. The optimal scenarios where masking is most impactful are those where community prevalence is at a medium level (around 2%) and transmissibility is high. Conclusions Masking by HCWs is an effective way to reduce nosocomial transmission to both patients and, especially, HCWs at all levels of mask effectiveness and adherence. Increases in adherence to a masking policy can provide a small but important impact. HCW-HCW transmission is the dominant source of HCW infections so universal HCW masking policies are most impactful should policy makers wish to target HCW infections. The more transmissible a virus/ variant in circulation is the more impactful masking by HCWs is for reducing nosocomial infections. Policy makers should consider implementing masking at the point when community prevalence is optimum for maximum impact.

  • Open Access

    Risk of unintended consequences from lower antibiotic prescribing for respiratory tract infections in primary care

    by James Stimson, Tricia M. McKeever, Emily Agnew, Wei Shen Lim, Simon Royal, Puja Myles, Stephanie Evans, Julie V. Robotham


  • Open Access

    The burden and dynamics of hospital-acquired SARS-CoV-2 in England

    by Ben S. Cooper, Stephanie Evans, Yalda Jafari, Thi Mui Pham, Yin Mo, Cherry Lim, Mark G. Pritchard, Diane Pople, Victoria Hall, James Stimson, et al.

    Hospital-based transmission had a dominant role in Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV) epidemics1,2, but large-scale studies of its role in the SARS-CoV-2 pandemic are lacking. Such transmission risks spreading the virus to the most vulnerable individuals and can have wider-scale impacts through hospital–community interactions. Using data from acute hospitals in England, we quantify within-hospital transmission, evaluate likely pathways of spread and factors associated with heightened transmission risk, and explore the wider dynamical consequences. We estimate that between June 2020 and March 2021 between 95,000 and 167,000 inpatients acquired SARS-CoV-2 in hospitals (1% to 2% of all hospital admissions in this period). Analysis of time series data provided evidence that patients who themselves acquired SARS-CoV-2 infection in hospital were the main sources of transmission to other patients. Increased transmission to inpatients was associated with hospitals having fewer single rooms and lower heated volume per bed. Moreover, we show that reducing hospital transmission could substantially enhance the efficiency of punctuated lockdown measures in suppressing community transmission. These findings reveal the previously unrecognized scale of hospital transmission, have direct implications for targeting of hospital control measures and highlight the need to design hospitals better equipped to limit the transmission of future high-consequence pathogens.


  • Open Access

    Estimation of the impact of hospital-onset SARS-CoV-2 infections on length of stay in English hospitals using causal inference

    by James Stimson, Koen B. Pouwels, Russell Hope, Ben S. Cooper, Anne M. Presanis, Julie V. Robotham

    Background: From March 2020 through August 2021, 97,762 hospital-onset SARS-CoV-2 infections were detected in English hospitals. Resulting excess length of stay (LoS) created a potentially substantial health and economic burden for patients and the NHS, but we are currently unaware of any published studies estimating this excess. Methods: We implemented appropriate causal inference methods to determine the extent to which observed additional hospital stay is attributable to the infection rather than the characteristics of the patients. Hospital admissions records were linked to SARS-CoV-2 test data to establish the study population (7.5 million) of all non-COVID-19 admissions to English hospitals from 1st March 2020 to 31st August 2021 with a stay of at least two days. The excess LoS due to hospital-onset SARS-CoV-2 infection was estimated as the difference between the mean LoS observed and in the counterfactual where infections do not occur. We used inverse probability weighted Kaplan–Meier curves to estimate the mean survival time if all hospital-onset SARS-CoV-2 infections were to be prevented, the weights being based on the daily probability of acquiring an infection. The analysis was carried out for four time periods, reflecting phases of the pandemic differing with respect to overall case numbers, testing policies, vaccine rollout and prevalence of variants. Results: The observed mean LoS of hospital-onset cases was higher than for non-COVID-19 hospital patients by 16, 20, 13 and 19 days over the four phases, respectively. However, when the causal inference approach was used to appropriately adjust for time to infection and confounding, the estimated mean excess LoS caused by hospital-onset SARS-CoV-2 was: 2.0 [95% confidence interval 1.8–2.2] days (Mar-Jun 2020), 1.4 [1.2–1.6] days (Sep–Dec 2020); 0.9 [0.7–1.1] days (Jan–Apr 2021); 1.5 [1.1–1.9] days (May–Aug 2021). Conclusions: Hospital-onset SARS-CoV-2 is associated with a small but notable excess LoS, equivalent to 130,000 bed days. The comparatively high LoS observed for hospital-onset COVID-19 patients is mostly explained by the timing of their infections relative to admission. Failing to account for confounding and time to infection leads to overestimates of additional length of stay and therefore overestimates costs of infections, leading to inaccurate evaluations of control strategies.


  • Open Access

    The burden and dynamics of hospital-acquired SARS-CoV-2 in England

    by Ben Cooper, Stephanie Evans, Yalda Jafari, Thi Mui Pham, Cherry Lim, Mark Pritchard, Diane Pople, Victoria Hall, James Stimson, David Eyre, et al.

    Hospital-based transmission played a dominant role in MERS-CoV and SARS-CoV epidemics but large-scale studies of its role in the SARS-CoV-2 pandemic are lacking. Such transmission risks spreading the virus to the most vulnerable individuals and can have wider-scale impacts through hospital-community interactions. Using data from acute hospitals in England we quantify within-hospital transmission, evaluate likely pathways of spread and factors associated with heightened transmission risk, and explore the wider dynamical consequences. We show that hospital transmission is likely to have been a major contributor to the burden of COVID-19 in England. We estimate that between June 2020 and March 2021 between 95,000 and 167,000 patients acquired SARS-CoV-2 in hospitals with nosocomially-infected patients likely to have been the main sources of transmission to other patients. Increased transmission to patients was associated with hospitals having fewer single rooms and lower heated volume per bed. Moreover, we show that reducing hospital transmission could substantially enhance the efficiency of punctuated lockdown measures in suppressing community transmission. These findings reveal the previously unrecognised scale of hospital transmission, have direct implications for targeting of hospital control measures, and highlight the need to design hospitals better-equipped to limit the transmission of future high consequence pathogens.


  • Open Access

    Evolution and emergence of multidrug-resistant Mycobacterium tuberculosis in Chisinau, Moldova

    by Tyler S. Brown, Vegard Eldholm, Ola Brynildsrud, Magnus Osnes, Natalie Levy, James Stimson, Caroline Colijn, Sofia Alexandru, Ecaterina Noroc, Nelly Ciobanu, et al.

    The evolution and emergence of drug-resistant tuberculosis (TB) has been studied extensively in some contexts, but the ecological drivers of these two processes remain poorly understood. This study sought to describe the joint evolutionary and epidemiological histories of a novel multidrug-resistant Mycobacterium tuberculosis strain recently identified in the capital city of the Republic of Moldova (MDR Ural/4.2), where genomic surveillance of drug-resistant M. tuberculosis has been limited thus far. Using whole genome sequence data and Bayesian phylogenomic methods, we reconstruct the stepwise acquisition of drug resistance mutations in the MDR Ural/4.2 strain, estimate its historical bacterial population size over time, and infer the migration history of this strain between Eastern European countries. We infer that MDR Ural/4.2 likely evolved (via acquisition of rpoB S450L, which confers resistance to rifampin) in the early 1990s, during a period of social turmoil following Moldovan independence from the Soviet Union. This strain subsequently underwent substantial population size expansion in the early 2000s, at a time when national guidelines encouraged inpatient treatment of TB patients. We infer exportation of this strain and its isoniazid-resistant ancestral precursor from Moldova to neighbouring countries starting as early as 1985. Our findings suggest temporal and ecological associations between specific public health practices, including inpatient hospitalization of drug-resistant TB cases from the early 2000s until 2013, and the evolution of drug-resistant M. tuberculosis in Moldova. These findings underscore the need for regional coordination in TB control and expanded genomic surveillance efforts across Eastern Europe.